You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

There was an error while loading. Please reload this page.

The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.